

2

MEDICINE EVALUATION PROCESSES ENVISAGED FOR SAHPRA

Jeanette Lotter (PhD) Director: Medicines Evaluation & Research South African Health Products Regulatory Authority

SAPRAA meeting: 13 April 2018, Midrand

Requested topics

- New submissions (NCE/clone/generic)
- Post-registration amendments
- Pre-Registration responses to Committee recommendations
- Pre-registration amendments



3

9.40_Changes_during_registration_process_Jun11_v1.pdf


- Write an official request (not an e-mail) to obtain permission for the change;
- Clearly indicate this as an additional change in the letter of application and in the Amendment Schedule;
- All the relevant documents and data as for a post-registration amendment have to be submitted;
- Arrange with Santhani for a set to be delivered to her, in order to have this for the inspectorate report and to amend the database in Siamed;
- This is not evaluated and approved separately by the inspectorate, but is done as part of the registration process;
- Final approval will therefore only be given when the registration certificate is issued.

Need for change

Delays in evaluation attributable to —



- increasing number of generic applications;
- registration without intent to market/distribute;
- historical procedures for fast-track;
- Iarge number of post-registration variations/amendments;
- IT systems and infrastructure;
- absence of project management and logistical support;
- Iimited abbreviated procedures and application of reliance models;
- availability of skilled technical reviewers.



"The" question

6


How do we optimise the regulatory decision-making process, within the framework of the Act, to improve efficiency?



High priority task team

- SAHPRA Board Committee: "Technical Operations & Regulatory Strategy" in collaboration with SAHPRA middle and senior managers
 - Section 2B(2) of the amended Medicines Act allows for information exchange, cooperation agreements, work-sharing and recognition of work done by other regulatory authorities → no longer a question of 'if', but when and how...
 - procedures, processes & requirements under development.
- Board resolution: imminent engagement with Industry groupings







Non-pharmacopoeial (newer) molecules

10


- Registration status with recognised NRAs, with access to the evaluation reports;
- Abridged evaluation process, focusing on countryspecific requirements.





What about abbreviated evaluation?

- Module $2 \rightarrow$ good overview and start to the evaluation;
- But the main review is based on module 3;
- However, a well written module 2 could allow the Regulator to base parts of the actual review on Module 2 (rather than Module 3), and only referring to module 3 for critical topics;
- Could therefore potentially ask for submission of only specific parts



"Without data another person with an opinion.

